当前位置: X-MOL 学术N. Engl. J. Med. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
The New England Journal of Medicine ( IF 96.2 ) Pub Date : 2022-09-22 , DOI: 10.1056/nejmoa2204705
Timothy M Miller 1 , Merit E Cudkowicz 1 , Angela Genge 1 , Pamela J Shaw 1 , Gen Sobue 1 , Robert C Bucelli 1 , Adriano Chiò 1 , Philip Van Damme 1 , Albert C Ludolph 1 , Jonathan D Glass 1 , Jinsy A Andrews 1 , Suma Babu 1 , Michael Benatar 1 , Christopher J McDermott 1 , Thos Cochrane 1 , Sowmya Chary 1 , Sheena Chew 1 , Han Zhu 1 , Fan Wu 1 , Ivan Nestorov 1 , Danielle Graham 1 , Peng Sun 1 , Manjit McNeill 1 , Laura Fanning 1 , Toby A Ferguson 1 , Stephanie Fradette 1 ,
Affiliation  

New England Journal of Medicine, Volume 387, Issue 12, Page 1099-1110, September 2022.


中文翻译:

反义寡核苷酸 Tofersen 用于 SOD1 ALS 的试验

新英格兰医学杂志,第 387 卷,第 12 期,第 1099-1110 页,2022 年 9 月。
更新日期:2022-09-22
down
wechat
bug